EMA: 5 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-08-03 14:52 (941 d 17:11 ago) – Posting: # 19133
Views: 3,227

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,358 posts in 4,459 threads, 1,492 registered users;
online 13 (0 registered, 13 guests [including 2 identified bots]).
Forum time: Tuesday 08:04 UTC (Europe/Vienna)

The interpretation of facts in a certain way
stimulates other scientists’ thoughts.    Róbert Bárány

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5